Engineered immune cells for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy that uses your own immune cells (T cells) that have been changed in the lab to find and attack leukemia cells that have a marker called CD84. It is for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 70 years.
- Diagnosed with acute myeloid leukemia (AML) that has returned or not improved after standard treatment.
- Your leukemia cells show a specific marker called CD84.
- You are generally in good health (able to care for yourself and up and about more than half of your waking hours).
- Your heart, liver, kidneys, and lungs are working well enough to safely receive this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called iNKT cells) that is designed to find and attack leukemia cells. It's for people whose leukemia has come back or hasn't gone away after standard treatments. The goal is to see if this therapy is safe and can help.
This early-stage study tests an experimental drug called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a protein called CD38 on leukemia cells, and the goal is to see if it is safe and helpful.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.